X
<

What to Expect from Intuitive Surgical's 3Q17 Earnings

PART:
1 2 3
What to Expect from Intuitive Surgical's 3Q17 Earnings PART 1 OF 3

Analysts’ Ratings for Intuitive Surgical before 3Q17 Earnings

3Q17 earnings release

Intuitive Surgical (ISRG) is set to announce its 3Q17 earnings results on October 19, 2017. The company is the leader in the surgical robotics market and has been growing at a fast pace in recent years. Over the past few weeks, ISRG stock has risen to new highs. On October 6, 2017, it was trading at a 52-week high of $367.50 per share. To find out more about the recent performance of ISRG stock, be sure to read Can Intuitive Surgical Sustain Its Current Stock Rally?

Analysts’ Ratings for Intuitive Surgical before 3Q17 Earnings

Interested in ISRG? Don't miss the next report.

Receive e-mail alerts for new research on ISRG

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Analysts’ recommendations for ISRG stock

Let’s take a look at Intuitive Surgical’s latest Wall Street analyst ratings, recommendations, and target prices for the next 12 months. According to rating recommendations provided by 18 brokerages in a Reuters survey, approximately 61.1% (or 11) of the analysts have given a “buy” rating for ISRG stock. Around 33.3% (or six) have rated the stock a “hold.” Only one analyst has recommended a “sell” for the stock.

Target price

A recommendation summary on ISRG stock over the next 12 months is provided in the chart above. As of October 12, 2017, ISRG’s consensus 12-month target price is $342.30, which implies a 12-month investment return potential of approximately -5.0% based on the stock’s closing price of $360.30 on October 11, 2017.

As of October 12, 2017, peers Medtronic (MDT), Stryker (SYK), and Becton Dickinson (BDX) have average broker target prices of $3.58, $91.10, and $152.05, respectively. The corresponding 12-month returns for these stocks are 131.0%, 14.6%, and 2.5%, respectively.

Latest rating updates

On October 10, 2017, Wedbush reaffirmed its “buy” rating for ISRG stock. The firm’s 12-month target price is $395 per share. That represents a potential upside of 9.6% for the next 12 months. Wedbush restated its recommendation on ISRG stock after the stock split on October 6, 2017. Wedbush had previously reiterated its “outperform” rating on the stock on September 25, 2017. The target price for the stock was $1,060. For more details on the stock split, read Intuitive Surgical’s Recent Stock Split: The Market Reaction.

For indirect exposure to Intuitive Surgical, you could consider investing in the PowerShares QQQ ETF (QQQ), which invests ~0.20% of its total investments in ISRG.

X

Please select a profession that best describes you: